Pular para o conteúdo
Menu
Mix Vale

Libbs stops sales of chronic migraine medication in Brazil

Beatriz
Por 4 min de leitura
Compartilhe
Mulher fechando os olhos com dor, aura por enxaqueca
Foto: Mulher fechando os olhos com dor, aura por enxaqueca - Sergey Mironov/shutterstock.com

The pharmaceutical company Libbs announced the discontinuation of Emgality, a medicine used to treat chronic migraines, on the Brazilian market. The decision was communicated to Anvisa on May 4th. The company did not detail the specific reasons that led to the closure of operations with the drug.

Publicidade

In an official statement, Libbs reported that the measure occurs “due to a portfolio update”. The medicine, marketed in partnership with Eli Lilly, which holds the patent, leaves the market after almost seven years of regulatory approval in the country.

Fármaco approved over six years ago

Emgality received authorization from Anvisa in November 2019. The drug’s active ingredient is galcanezumab, a molecule that acts to reduce the frequency and intensity of chronic migraine attacks in adult patients. Desde was then available for medical prescription and commercialization in Brazilian pharmacies.

Publicidade

Chronic migraine affects approximately 2% of the world’s population. No Brasil, it is estimated that around 15 million people suffer from some form of migraine, with chronic migraines being responsible for significant impacts on patients’ quality of life and professional productivity. Medicamentos like Emgality represented an important therapeutic option for refractory cases.

Discontinuation of Emgality does not immediately affect patients undergoing treatment. Aqueles who use the drug will be able to continue using their current stocks. Contudo, after the end of sales by Libbs, new patients will no longer have access to the medicine through prescription on Brasil.

Meningite, severe pain in the head
severe pain in the head – Tunatura/ Shutterstock.com

Impacto for patients undergoing treatment

Pacientes who depend on Emgality will have to seek therapeutic alternatives from their doctors. The Brazilian market offers other options for the treatment of chronic migraine, including medications with similar mechanisms of action and different pharmacological approaches. The medical decision about which medication to use must consider specific characteristics of each patient.

Existem other injectable molecules approved by Anvisa for chronic migraine:

  • Anticorpos monoclonal against CGRP (calcitonin gene-related peptide)
  • Medicamentos preventive orals of different therapeutic classes
  • Terapias intravenous for more severe cases
  • Tratamentos with botulinum toxin approved specifically for migraine

The transition to new medications requires medical monitoring. Alguns patients may have a better response to one drug compared to another, which is why individualized assessment is essential. Além Furthermore, issues related to health plan coverage and reimbursement policies can influence therapeutic choice.

Publicidade

Contexto from discontinuation

The pharmaceutical company Libbs did not disclose detailed information about factors that led to the discontinuation. Empresas of pharmaceuticals frequently make adjustments to their portfolios for commercial, financial or strategic reasons. Analysis of sales performance, market perspectives and alignment with corporate objectives are part of these decisions.

Brasil represents a significant market for pharmaceuticals, but certain pharmaceuticals may be in lower demand compared to other geographies. The concentration of resources on medicines with higher sales volume or higher profit margins is a common practice in the pharmaceutical sector.

Eli Lilly, owner of the formula, maintains operations in other markets. The specific decision to discontinue Brasil does not necessarily imply the global closure of Emgality. Diferentes commercial strategies can be adopted in each country according to local analysis.

Reações in the healthcare sector

The medical community awaits official communications from Libbs and potential guidance from Anvisa regarding the transition. Associações from patients and organizations focused on neurology may speak out about the impact of this discontinuation. Anvisa, as a regulatory body, monitors access to medicines and possible therapeutic gaps in the market.

Profissionais who prescribe Emgality will need to update treatment protocols and inform their patients of the changes. Clear communication between doctors and patients is essential to ensure continuity of care and avoid abrupt interruptions in treatment.

Nenhum public statement from medical or patient rights organizations had been released at press time. The community awaits positions that better contextualize the implications of the measure for people with chronic migraines in Brasil.

Publicidade

Beatriz Lima é colaboradora da redação do Mix Vale, portal de notícias com cobertura de Brasil e mundo. Produz conteúdo nas editorias de economia e benefícios, com foco em informação de serviço para o leitor brasileiro. Escreve para o portal desde 2024.

Notícias relacionadas

Mais lidas

  1. Ciência

    Meteoro no Nordeste: bólido cruza o céu de cinco estados às 21h34 e mobiliza buscas por fragmentos na Paraíba

  2. Caixa Econômica Federal

    Pé-de-Meia paga parcela de R$ 1.000,00 a aprovados no ensino médio de 2026 entre fevereiro e março de 2027

  3. Política

    Com obstrução parcial no intestino, Jair Bolsonaro é internado no hospital DF Star em Brasília

  4. INSS

    Recuperação da senha Gov.br pelo celular exige reconhecimento facial ou código por SMS para o Meu INSS

  5. EUA

    Terremoto em Los Angeles atinge magnitude 4,2 e causa tremores leves em Commerce na madrugada

  6. Matéria Publicitária

    MineMV é o novo jogo grátis de construir com blocos; veja como jogar e liberado para todas as idades

  7. Política

    Regulamentação da escala 5×2 pelo governo encarece cálculo da hora extra a partir de 16 de dezembro

  8. Santa Catarina

    Acidente de trânsito na SC-108 envolve carro e moto e deixa motociclista morto em São Ludgero

  9. Mundo

    Jornalista italiano Corrado Augias morre aos 91 anos; presidente da Itália lamenta a perda

  10. Loterias

    Rendimento de R$ 40 milhões da Mega-Sena 3088 chega a R$ 337 mil por mês no Tesouro Direto